pmf104

Paolo M. Fortina, MD, PhD

Contact Dr. Fortina

233 South 10th Street
BLSB 1009
Philadelphia, PA 19107

(215) 955-0683
(215) 503-9142 fax

Most Recent Peer-reviewed Publications

  1. Detection and characterization of circulating tumor associated cells in metastatic breast cancer
  2. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine
  3. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  4. The future of laboratory medicine - A 2014 perspective
  5. Clinical exome performance for reporting secondary genetic findings
  6. Performance of exome sequencing for pharmacogenomics
  7. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer
  8. Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis
  9. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  10. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer
  11. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics
  12. The human platelet: Strong transcriptome correlations among individuals associate weakly with the platelet proteome
  13. Genomic test validation for incidental findings
  14. Clinical genomics: When whole genome sequencing is like a whole-body CT scan
  15. Mechanisms of endothelial cell attachment, proliferation, and differentiation on 4 types of platinum-based endovascular coils
  16. Genomics into Healthcare: The 5th Pan Arab Human Genetics Conference and 2013 Golden Helix Symposium
  17. Donor splice-site mutation in CUL4B is likely cause of X-linked intellectual disability
  18. Bridging genomics research between developed and developing countries: The Genomic Medicine Alliance
  19. Functional significance of macrophage-derived exosomes in inflammation and pain
  20. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors